Lung cancer in China: current and prospect
- PMID: 33165004
- DOI: 10.1097/CCO.0000000000000703
Lung cancer in China: current and prospect
Abstract
Purpose of review: To describe the current status of lung cancer in China, including incidence, prevention, molecular testing and treatment.
Recent findings: Lung cancer presents a major public health issue and an enormous burden on society in China, because of its increasing incidence and high mortality. Several distinct gene profiles were associated with lung cancer in China: high EGFR mutation rate, low KRAS mutation rate and more comorbidity of HBV infection. Thus, local Chinese Society of Clinical Oncology Guidelines with more consideration of drug accessibility, regional development differences were highly recommended for clinical practice. For treatment, targeted therapy has achieved fruitful progress. Immunotherapy in China was a little bit lag behind previously and now there is a surge of immunotherapeutic drugs under investigation. For future, more preventive strategies and more trials considering chrematistics of Chinese lung cancer are needed.
Summary: There are achievements and shortcomings for lung cancer prevention and treatment in China. More work considering distinct characteristic of lung caner in China are needed.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2002. CA Cancer J Clin 2020; 70:7–30.
-
- Zheng RHSK, Zhang SW, Zeng HM, et al. Report of cancer epidemiology in China, 2015. Chin J Oncol 2019; 41:19–28.
-
- Chen WQZS, Zeng HM, et al. Report of cancer incidence and mortality in China, 2010. China Cancer 2014; 23:1–10.
-
- Cao M, Chen W. Epidemiology of lung cancer in China. Thorac Cancer 2019; 10:3–7.
-
- Wang N, Mengersen K, Tong S, et al. Lung cancer mortality in China: spatial and temporal trends among subpopulations. Chest 2019; 156:972–983.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
